Advances in biopharma chromatography technology

New recombinant protein A affinity chromatography resin responds to the industry’s need for greater efficiency in monoclonal antibodies (mAbs) processing, helping to bring life-changing therapies to market faster.

Biopharma researcher in lab

Recombinant protein A affinity chromatography resin

Recombinant protein A affinity chromatography resin

According to a National Center for Biotechnology Information publication, protein A chromatography is a proven downstream purification process in commercializing mAbs. Yet there remains a need to reduce the total purification steps while improving purity and yield.

PROchievA resins The BAKERBOND® PROchievA affinity chromatography resin offers a new process choice to biopharmaceutical manufacturers in the first chromatography step of mAbs production, without disrupting production workflow processes or protocols.

Avantor® developed the BAKERBOND® PROchievA resin to address key industry needs in the following ways:

  • The new resin uses a novel, proprietary ligand to provide best-in-class purification in critical protein A chromatography step of mAbs manufacturing
  • BAKERBOND® PROchievA resin has shown excellent dynamic binding capacity for mAbs in performance tests conducted against comparable protein A resins on the market today
  • It has demonstrated improved purification results in emerging, complex molecules, such as Fc-Fusion proteins and similar IgG antibody-like molecules
  • The resin’s particle size and porous yet rigid nature of agarose base allows for higher flow, resulting in higher efficiency in downstream processing
J.T.Baker® BAKERBOND® PROchievA recombinant protein A affinity chromatography resin

I am interested in learning more details about Avantor’s new BAKERBOND® PROchievA resin.

Improved supply chain security and performance

With the BAKERBOND® PROchievA resin, Avantor ensures an independent chromatography resin supply alternative to existing purification products is commercially available, providing greater supply chain flexibility and security along with purification that demonstrates best-in-class performance.

In several applications, the BAKERBOND® PROchievA resin was shown to deliver higher levels of protein purity post-protein A chromatography, thus reducing the burden on subsequent purification operations. These include several examples in the emerging market for Fc-Fusion proteins (Fig.1).

Fc-Fusion protein study comparison

The new resin enhances Avantor’s J.T.Baker® family of products for biopharmaceutical research and production. Avantor’s J.T.Baker® brand chromatography products allow biopharma manufacturers to realize higher production efficiencies, meet stringent regulatory requirements and accelerate regulatory approval in bringing new therapies to market.